rney's Docket No. 1543.201 (5784-81A)

APR 1 6 2001

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Whitehouse

Appl. No.:

09/771,302

Group Art Unit: Not yet assigned

Filed:

January 26, 2001

Examiner:

Not yet assigned

For:

ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF-2

AND METHOD OF USE

April 13, 2001

Commissioner for Patents Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT CITATION UNDER 37 C.F.R. § 1.97

Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each identified document. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,

Leslie T. Henry

Registration No. 45,714

Customer No. 000826 **ALSTON & BIRD LLP**

Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Raleigh Office (919) 420-2200 Fax Raleigh Office (919) 420-2260

"Express Mail" Mailing Label Number Date of Deposit: April 13, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Commissioner of Patents, Washington, DC 20231.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Washington, DC 20231, on April 13, 2001.

0300

PATENT

6 2000 Attorney's Docket No. 1543.201 (5784-81A)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Whitehouse

Appl No.:

09/771,302

Group Art Unit:

Not yet assigned

Filed:

January 26, 2001

Examiner:

Not yet assigned

For:

ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF-2

AND METHOD OF USE

April 12, 2001

Commissioner for Patents Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT CITATION UNDER 37 C.F.R. § 1.97

Sir:

Attached is a list of documents on form PTO-1449. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

All items are attached except those that were supplied in parent Application No. 09/385,114 filed August 27, 1999. Since the benefit of this application was claimed under 35 U.S.C. 120, no copies need to be furnished in accordance with 37 C.F.R. 1.98(d); however, copies will be furnished on request.

Respectfully submitted,

Leslie T. Henry

Registration No. 45,714

Customer No. 000826 **ALSTON & BIRD LLP** Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Raleigh Office (919) 420-2200 Fax Raleigh Office (919) 420-2260

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Washington, DC 20231, on April 12, 2001.